Hatteras’ mission is to build transformational human medicine companies that benefit patients and the professionals who serve them. Over half of our portfolio companies were created with our initial investment.

At Hatteras Venture Partners, we believe that breakthrough science and entrepreneurial innovation have the power to create valuable new ways of treating and diagnosing disease, providing value for our investors and transforming human health.

The Hatteras team brings operational experience, a renowned strategic partner network, and a successful investment track record. We are passionate about utilizing our backgrounds to engage entrepreneurs and enhance the value of their companies.


Latest News

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-going Research, Team Expansion, and Manufacturing Buildup

December 4, 2017

New strategic investor bioMérieux will explore collaborative opportunities around Qvella’s Field Activated Sample Treatment (FAST™) technology in complementary markets December 4, 2017 — TORONTO — Qvella, a leading molecular diagnostics…

More News